Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Other Non-Current Assets (2023 - 2026)

MoonLake Immunotherapeutics' Other Non-Current Assets history spans 4 years, with the latest figure at $1.3 million for Q1 2026.

  • Quarterly Other Non-Current Assets fell 20.85% to $1.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Mar 2026, down 20.85% year-over-year, with the annual reading at $596000.0 for FY2025, N/A changed from the prior year.
  • Other Non-Current Assets came in at $1.3 million for Q1 2026, up from $596000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $8.4 million in Q4 2023 to a low of $587000.0 in Q3 2025.
  • The 4-year median for Other Non-Current Assets is $1.7 million (2025), against an average of $3.0 million.
  • Year-over-year, Other Non-Current Assets plummeted 73.13% in 2025 and then fell 20.85% in 2026.
  • MoonLake Immunotherapeutics' Other Non-Current Assets stood at $8.4 million in 2023, then tumbled by 75.49% to $2.1 million in 2024, then tumbled by 71.13% to $596000.0 in 2025, then soared by 125.5% to $1.3 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Other Non-Current Assets are $1.3 million (Q1 2026), $596000.0 (Q4 2025), and $587000.0 (Q3 2025).